Vice Chairman of the Exchange Zhao Long (fourth from right), Fubon Securities General Manager Kuo Yong-yi (third from right), and Eternal Hong Biotech Chairman Chung Wei-kai (fourth from left) attended the listing ceremony. Eternal Hong International Biotech (6936) today (28th) officially listed at an offering price of NT$28.01 per share, injecting fresh energy into the biotechnology sector of the Taiwan capital market.

Eternal Hong Biotech specializes in a range of animal health products, from preventive care to disease treatment, holding various microbial culture production techniques and prescription experience, along with multiple domestic and international drug certifications, establishing a leading position in animal healthcare. Fubon Securities General Manager Kuo Yong-yi remarked during the ceremony that Eternal Hong Biotech produces therapeutic animal drugs, feed additives, as well as medications and health products for pets, confirming its status as the largest animal pharmaceutical manufacturer in the country, with rich process experience allowing for customized formulations for clients.

Additionally, Eternal Hong Biotech is committed to developing sustainable livestock products, receiving recognition with the Agricultural Department’s innovation award. The company collaborates with major American firms to develop green aquaculture enzyme products and provides OEM services. Chairman Chung Wei-kai emphasized that the company has been active in the animal healthcare sector for many years, and today's listing marks the beginning of a new milestone. Eternal Hong Biotech is actively expanding into overseas markets in Asia and Europe and aims to establish itself as an international brand in animal healthcare, focusing on creating maximum value for customers, employees, and investors in the future.

According to recent data, Eternal Hong Biotech reported a revenue of NT$1.294 billion for the year 113, with earnings per share after tax at NT$2.06, indicating growth of 7.17% and 49.28% respectively compared to the previous year—showing impressive operational results. The company’s board of directors approved a plan to distribute a cash dividend of NT$1.85 per share for the fiscal year 114, as a token of appreciation for shareholders’ support.